Chimeric antigen receptor T‐cell therapy for marrow and extramedullary relapse of infant acute lymphoblastic leukemia

Autor:	Lauren Pommert, Amy Moskop, Pooja D. Thakrar, Julie Talano, Rachel Phelan
Rok vydání:	2020
Předmět:	medicine.medical_treatment Immunotherapy Adoptive 03 medical and health sciences 0302 clinical medicine Refractory Antigen hemic and lymphatic diseases Antineoplastic Combined Chemotherapy Protocols Humans Medicine Receptors Chimeric Antigen biology business.industry Hematopoietic Stem Cell Transplantation Infant Histone-Lysine N-Methyltransferase Hematology Immunotherapy Precursor Cell Lymphoblastic Leukemia-Lymphoma Prognosis medicine.disease Combined Modality Therapy Kidney Neoplasms Chimeric antigen receptor Infant Acute Lymphoblastic Leukemia Leukemia KMT2A Oncology 030220 oncology & carcinogenesis Mutation Pediatrics Perinatology and Child Health biology.protein Cancer research Female Chimeric Antigen Receptor T-Cell Therapy Neoplasm Recurrence Local Bone Marrow Neoplasms business Myeloid-Lymphoid Leukemia Protein 030215 immunology
Zdroj:	Pediatric Blood & Cancer. 68
ISSN:	1545-5017 1545-5009
Popis:	Chimeric antigen receptor (CAR) T-cells, engineered autologous T-cells that target antigens found in leukemia, have shown durable remissions in relapsed acute lymphoblastic leukemia (ALL). Infant ALL with KMT2A rearrangements (KMT2Ar) is a rare, aggressive form of leukemia associated with extramedullary disease both at diagnosis and at relapse, and overall outcomes for these patients are dismal. Here we report the successful use of tisagenlecleucel, a CAR T-cell product approved for relapsed/refractory ALL, in a patient with KMT2Ar infant ALL who was treated for combined marrow and extramedullary (renal) relapse.
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6d38a7802def412a449681966fac0489 https://doi.org/10.1002/pbc.28739 Zobrazit plný text záznamu Plný text